Quoin posts Q2 net loss $2.1M, reports positive clinical data for first Netherton Syndrome subject

Quoin Pharmaceuticals, Ltd.

Cash, equivalents and securities at June 30, 2023: ~$15.4M; runway extends into 2H 2024.
Net loss Q2 2023: ~$2.1M vs ~$2.7M in Q2 2022; first-half 2023 loss ~$4.7M.
First subject in open-label Netherton Syndrome study showed fully clear skin at QRX003 treatment sites and substantial pruritis improvement.
Majority of patients across both Netherton Syndrome studies expected to be enrolled by end of August 2023.
Regained Nasdaq minimum bid price compliance; closing bid price at $1.00+ for 10 consecutive days.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Quoin Pharmaceuticals, Ltd. reported quarter ended June 30, 2023 results: net income Net loss for the quarter ended June 30, 2023 was approximately $2.1 million compared to approximately $2.7 million for t.

Period: quarter ended June 30, 2023
Net income: Net loss for the quarter ended June 30, 2023 was approximately $2.1 million compared to approximately $2.7 million for t
Result: reported results

Exact text from the filing

On August 2, 2023, Quoin Pharmaceuticals Ltd. (the “Company”) announced its financial results for the quarter ended June 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Quoin Pharmaceuticals, Ltd. filing history →

Source: SEC EDGAR

accession 0001104659-23-086860

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.